Navigation Links
Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness

to update any forward-looking statements contained in this document as a result of new information or future events or developments. Thus, it should not be assumed that the Company's silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements.

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

WYETH DISCLOSURE NOTICE: The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products, including with respect to our pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property a
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:7/29/2014)... N.J., July 29, 2014  Covance Inc. (NYSE: ... quarter ended June 30, 2014.  Net revenue was $639 ... 2013.  On a GAAP basis, the company reported earnings ... The company reported pro forma earnings per diluted share ... 2013. Pro forma results exclude asset impairment charges totaling ...
(Date:7/29/2014)... 29  2014 ISPE—the International Society for Pharmaceutical ... Bournas as President and CEO, succeeding ... the Society last fall.  Mr. Bournas takes the ... healthcare association industry as well as significant international ... vision for the expansion of its global initiatives ...
(Date:7/29/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence ... Clinical Lab Expo today by unveiling two booths (#1209 ... partnering with customers to redefine the value of the ... that they,re looking for a partner to help them ... offices," said Jack Phillips , president and CEO ...
Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
... SUNNYVALE, Calif., Dec. 5, 2010 Pharmacyclics, Inc. (Nasdaq: ... Chronic Lymphocytic Leukemia (CLL) presentations at the American Society ... PCI-32765.  Two presentations report preclinical data, and one presentation ... patients with CLL or Small Lymphocytic Lymphoma (SLL) treated ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 7
(Date:7/29/2014)... 30, 2014 Recently, iFitDress.com, a well-known wedding ... satin bridal gowns . Aside from this, it has ... up to 68 percent off. All of its old and ... The company’s sales representative says excitedly, “We are pleased to ... new range, there are a lot of amazing items. It ...
(Date:7/29/2014)... St. Petersburg, FL (PRWEB) July 30, 2014 Phytceramides ... explains how and why in her new book. , Today is ... Phytoceramides: Anti Aging At Its Best . The book is ... larger skin care book, but felt that Phytoceramides were ... sense to bring out this focused book now," says Kathy Heshelow, ...
(Date:7/29/2014)... (PRWEB) July 30, 2014 Dignity Sciences ... successful completion of a Phase I trial with DS107G, ... , This study was a randomized, placebo-controlled, double-blind, single-ascending ... the safety, pharmacokinetics and effect of food on DS107G ... benign safety profile of DGLA following both single and ...
(Date:7/29/2014)... VA (PRWEB) July 29, 2014 The ... members of the Deadliest Cancer Coalition, led advocacy efforts ... officials in the newly established Congressional Caucus on the Deadliest ... efforts, the caucus now features the following 20 members: , ... Eshoo (CA-18) – May 2, 2014, Rep. Zoe Lofgren (CA-19) ...
(Date:7/29/2014)... researchers say they have discovered a chemical alteration in ... if confirmed in larger studies, could give doctors a ... of attempting suicide. , The discovery, described online in ... changes in a gene involved in the function of ... role in turning what might otherwise be an unremarkable ...
Breaking Medicine News(10 mins):Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 2Health News:Mesothelioma Organization Works to Add Members to ‘Deadliest Cancer Caucus’ 3Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3
... them women, suffer from lupus, a disease where the ... week marks a significant step forward in understanding how ... new studies identifying genes involved in this often debilitating ... of the division of Rheumatology and director of Rheumatology ...
... length, group advises , , SUNDAY, Jan. 20 (HealthDay News) -- ... illness, it can be a challenge to take care of ... serious complications, says the American Diabetes Association. , "People ... weather," Ann Albright, the ADA,s president of health care and ...
... Jan. 18 Following the New Hampshire primary,a headline ... life.", Ironically, Joe Dolphin, who announced his endorsement ... a lung transplant, is also hoping,to receive breath that ... leader has suffered for many years with AAT (Alpha-1 ...
... has been named the national lead center for ... pediatric heart pump called Berlin Heart EXCOR® Pediatric ... MD, chief of pediatric and congenital heart surgery ... Department of Surgery at Baylor College of Medicine, ...
... Pharmacyclics,Inc. (Nasdaq: PCYC ) today announced ... its second quarter 2008 financial results and achievements ... (1:30 p.m. PDT)., To participate in the ... 706-758-3306 for international callers and reference,conference passcode, 31926585. ...
... from,the Academy of Columbus, an Imagine charter school, will ... A Smile! Day state kick-off in,Columbus on Friday, Feb.1., ... in the Atrium at the,Ohio Statehouse with dentists, dental ... of Dentistry, legislators and other,dignitaries participating. At the event, ...
Cached Medicine News:Health News:NEJM editorial on significance and limitations of new lupus gene expression research 2Health News:NEJM editorial on significance and limitations of new lupus gene expression research 3Health News:NEJM editorial on significance and limitations of new lupus gene expression research 4Health News:Illness Presents Diabetics With Special Challenges 2Health News:Long-Time San Diego Community Leader, Transplant Patient, Joe Dolphin, Endorses John Mccain 2Health News:National study will look at German-made heart pump for children needing heart transplants 2Health News:National study will look at German-made heart pump for children needing heart transplants 3Health News:Statehouse Atrium to be Site for Children's Dental Access Event - Ohio Legislators to Mingle With Children and Dentists for This Free Care Event! 2
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: